Overview
Genomic medicine firm's Q4 revenue rose yr/yr but missed analyst expectations
Company posted Q4 net loss of $37.4 mln, or $0.11 per share
Raised over $130 mln since start of 2025 through licensing, milestones and equity financing
Outlook
Sangamo expects 2026 GAAP operating expenses of $120 mln to $140 mln, subject to funding
Company sees 2026 non-GAAP operating expenses at $110 mln to $120 mln, excluding stock comp and D&A
Sangamo expects current cash and recent financings to fund operations into Q3 2026
Result Drivers
PFIZER LICENSE PAYMENT - Q4 revenue increase was mainly due to $6 mln in revenue from Pfizer’s exercise of a licensing option
INCREASED CLINICAL AND MANUFACTURING COSTS - Higher Q4 operating expenses were driven by increased clinical and manufacturing costs related to BLA readiness for the Fabry disease program
IMPAIRMENT CHARGES - Q4 operating expenses rose due to impairment charges on long-lived assets
Company press release: ID:nGNX5D3V0C
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $14.2 mln | $20.30 mln (3 Analysts) |
Q4 EPS | -$0.11 | ||
Q4 Net Income | -$37.4 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $2.00, about 523.2% above its March 27 closing price of $0.32
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments